Skip to content

The effect of Zishen Yutai pills on the improvement of IVF oocyte utilization rate in POI patients: a prospective multicenter randomized controlled trial

The effect of Zishen Yutai pills on the improvement of IVF oocyte utilization rate in POI patients: a prospective multicenter randomized controlled trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000031767
Enrollment
Unknown
Registered
2020-04-09
Start date
2020-06-01
Completion date
Unknown
Last updated
2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

premature ovarian insufficiency

Interventions

Sponsors

Reproductive Medical Center of Ruijin Hospital School of Medicine, Shanghai Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Volunteer to participate in this study, be willing to use medication according to the treatment plan and follow up, and sign the informed consent; 2. The patient was in good health, and there were no obvious abnormalities in clinical physical examination and laboratory examination (except for POI related indicators); 3. Aged between 20 and 40 years; Conforming to the preliminary screening conditions of POI (Poseidon Group 3 and Group 4) as ovarian basal sinus follicles less than 5; AMH <1.2ng/ml; 4. Hysteroscopy or fallopian tube examination: the uterine cavity shape is normal; normal uterine cavity shape after the operation drugs and the like; 5. The karyotype of the couple is normal and there is no genetic disease.

Exclusion criteria

Exclusion criteria: 1. Patients with severe diseases of the respiratory system or endocrine system or nervous system or cardiovascular system or diseases of the digestive system or genitourinary system or family history of hereditary diseases; 2. Who has suffered from or is suffering from contraindications of Zishen Yutai pills or alleric to Zishen Yutai pills; 3. Smoking more than 20 cigarettes a day; 4. Patients with genital tract virus infection and cervical laxity; With reproductive organ malformation or chromosome abnormality; 5. Patients with HBV, HCV, HIV or severe autoimmune diseases or tumors or cancers; 6. Patients with endometrial lesions.

Design outcomes

Primary

MeasureTime frame
oocyte utilization rate;

Secondary

MeasureTime frame
implantation rate (number of pregnant cases which are confirmed by blood ß-hCG examination / number of transplanted cases);multiple pregnancy rate (Number of twins and above cases/number of pregnant cases which are confirmed by ultrasound);early miscarriage rate (number of miscarriage cases / number of pregnant cases confirmed by ultrasound);late miscarriage rate (number of miscarriage cases / number of pregnant cases confirmed by ultrasound);premature birth rate (number of premature births/ number of pregnant cases confirmed by ultrasound);live birth rate (number of deliveries / number of transplantation cycles);number of retrieved oocytes;fertilization rate (number of fertilized oocytes / number of retrieved oocytes);cleavage rate;Effective embryo rate;high qualified embryo rate;Adverse reaction rate;Cancellation rate;Clinical pregnancy rate (Clinical pregnancies/total number of embryo transfer cycles);

Countries

China

Contacts

Public ContactAijun Zhang

Reproductive Medical Center of Ruijin Hospital School of Medicine, Shanghai Jiaotong University

zhaj1268@163.com+86 13916629178

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026